NADAC acquisition cost data for LUMIGAN 0.01% EYE DROPS. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00023320508 | $87.39 | 2022-01-14 | Rx |
| 00023320505 | $87.50 | 2022-01-14 | Rx |
| 00023320503 | $87.53 | 2022-01-14 | Rx |
| 00023320503 | $87.53 | 2022-01-14 | Rx |
| 00023320505 | $87.50 | 2022-01-14 | Rx |
| 00023320508 | $87.39 | 2022-01-14 | Rx |
| 00023320508 | $87.39 | 2022-01-14 | Rx |
| 00023320505 | $87.50 | 2022-01-14 | Rx |
| 00023320503 | $87.53 | 2022-01-14 | Rx |
| 00023320508 | $87.39 | 2022-01-14 | Rx |
Generic: Bimatoprost | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $594.4M | 1,744,546 | 393,665 | $79.03 |
| 2020 | $633.5M | 1,718,576 | 382,851 | $83.29 |
| 2021 | $668.7M | 1,674,825 | 388,372 | $88.69 |
| 2022 | $701.3M | 1,606,849 | 366,333 | $94.15 |
| 2023 | $697.0M | 1,480,360 | 347,753 | $99.66 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $75.2M | 160,404 | 37,580 |
| New York | $73.3M | 139,982 | 34,288 |
| Florida | $65.1M | 153,162 | 34,270 |
| Texas | $50.6M | 101,081 | 26,781 |
| Pennsylvania | $44.5M | 96,989 | 23,201 |
| New Jersey | $27.9M | 54,004 | 13,771 |
| Georgia | $26.2M | 51,548 | 13,501 |
| North Carolina | $21.1M | 46,005 | 11,022 |
| Illinois | $20.9M | 42,497 | 10,305 |
| Puerto Rico | $20.7M | 76,735 | 12,080 |
| Ohio | $17.5M | 35,903 | 9,039 |
| Michigan | $15.8M | 32,916 | 8,693 |
| Arizona | $14.5M | 27,913 | 7,279 |
| Tennessee | $13.9M | 28,625 | 7,344 |
| Missouri | $13.6M | 29,568 | 7,057 |
| Connecticut | $13.5M | 23,052 | 6,336 |
| Virginia | $13.3M | 26,213 | 6,927 |
| South Carolina | $12.2M | 25,412 | 6,554 |
| Indiana | $12.2M | 24,042 | 6,206 |
| Massachusetts | $12.1M | 23,231 | 6,047 |
| Maryland | $11.0M | 19,012 | 5,627 |
| Alabama | $10.4M | 24,301 | 5,707 |
| Louisiana | $8.9M | 20,892 | 4,798 |
| Kentucky | $7.8M | 16,641 | 4,014 |
| Mississippi | $7.6M | 17,751 | 4,117 |
| Wisconsin | $6.9M | 14,482 | 3,526 |
| Iowa | $6.4M | 14,699 | 3,295 |
| Minnesota | $6.2M | 13,653 | 3,147 |
| Colorado | $6.1M | 12,004 | 2,939 |
| Washington | $6.0M | 11,670 | 2,963 |
| Oklahoma | $5.5M | 11,887 | 3,038 |
| Maine | $4.9M | 8,257 | 2,398 |
| Kansas | $4.1M | 9,476 | 2,136 |
| Nevada | $3.9M | 7,540 | 2,017 |
| Arkansas | $3.8M | 9,655 | 2,082 |
| New Mexico | $3.5M | 7,631 | 1,756 |
| New Hampshire | $2.9M | 5,219 | 1,438 |
| Nebraska | $2.9M | 6,640 | 1,508 |
| Oregon | $2.8M | 5,796 | 1,461 |
| Utah | $2.5M | 4,914 | 1,359 |
| West Virginia | $2.5M | 5,242 | 1,279 |
| Hawaii | $2.4M | 3,731 | 1,248 |
| Rhode Island | $2.4M | 5,610 | 1,289 |
| Delaware | $1.8M | 3,212 | 939 |
| South Dakota | $1.5M | 3,688 | 805 |
| Montana | $1.4M | 3,031 | 725 |
| Vermont | $1.3M | 2,497 | 651 |
| North Dakota | $1.3M | 3,264 | 648 |
| Alaska | $1.2M | 1,989 | 582 |
| Idaho | $1.1M | 2,346 | 590 |
| District of Columbia | $1.1M | 1,890 | 579 |
| Wyoming | $828.5K | 1,858 | 420 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.